<DOC>
	<DOC>NCT00071006</DOC>
	<brief_summary>The study tests the safety and efficacy of axitinib in patients who have the hematologic disease of Acute Myeloid Leukemia or Myelodysplastic Syndrome. The study tests patients who have poor prognosis before entering the study.</brief_summary>
	<brief_title>AG-013736 (Axitinib) In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS)</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Axitinib</mesh_term>
	<criteria>Poor prognosis AML or MDS Histological confirmation of diagnosis White blood cell count less than or equal to 30,000/mm3 Adequate hepatic and renal function documented within 14 days prior to registration Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 No evidence of preexisting uncontrolled hypertension Not a suitable candidate for chemotherapy No prior systemic chemotherapy treatment for AML or MDS or treatment with an antiangiogenesis agent Patients must not have exclusion criteria. Candidate for chemotherapy Patients with AML M3 (acute promyelocytic leukemia) Conditions that might confound the evaluation of safety or efficacy or increase patient risk.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>